Zimmer Biomet Holdings, Inc. $ZBH Shares Purchased by Brandes Investment Partners LP

Brandes Investment Partners LP grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 215.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 48,863 shares of the medical equipment provider’s stock after purchasing an additional 33,368 shares during the period. Brandes Investment Partners LP’s holdings in Zimmer Biomet were worth $4,394,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Brighton Jones LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $204,000. Sivia Capital Partners LLC purchased a new stake in shares of Zimmer Biomet during the 2nd quarter worth about $232,000. United Bank raised its stake in shares of Zimmer Biomet by 10.7% in the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock valued at $1,085,000 after acquiring an additional 1,153 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of Zimmer Biomet by 129.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after acquiring an additional 1,202 shares in the last quarter. Finally, Cerity Partners LLC raised its stake in shares of Zimmer Biomet by 93.6% in the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after acquiring an additional 37,116 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH opened at $88.45 on Thursday. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The firm has a market capitalization of $17.11 billion, a PE ratio of 22.97, a PEG ratio of 2.07 and a beta of 0.47. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The business’s 50-day simple moving average is $87.67 and its 200 day simple moving average is $90.48.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.23. The firm had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.94%.

Analysts Set New Price Targets

ZBH has been the topic of several recent research reports. Leerink Partners initiated coverage on Zimmer Biomet in a report on Monday, April 13th. They set a “hold” rating and a $101.00 price objective on the stock. Truist Financial reaffirmed a “hold” rating and issued a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. BTIG Research reaffirmed a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Wells Fargo & Company decreased their price target on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. Finally, Stifel Nicolaus decreased their price target on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $102.70.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.